There is growing evidence that suggests that the suppression of angiotensin II receptor signaling by AT1R blockers can inhibit tumor progression in several types of cancers including renal, colon, breast, bladder, and prostate cancer (Piastowska-Ciesielska et al., 2013[39]; Arrieta et al., 2015[7]; Asgharzadeh et al., 2018[10], 2020[9]; Hashemzehi et al., 2021[23][24]). The gene discussed is AGTR1; the disease is neoplasm.